Gri Bio, Inc. (GRI)
NASDAQ:GRI
Want to see GRI full AI Analyst Report?
Top Page
GRI Bio
(NASDAQ:GRI)
Select Model
Select Model
Rating:46Neutral
Price Target:
$2.00
▲(614.29% Upside)
Action:Reiterated
Date:06/19/26
The score is held down primarily by weak financial performance (large losses and significant cash burn) and bearish technicals (price below key moving averages with negative MACD). Positive corporate catalysts (Orphan Drug Designation and encouraging Phase 2a updates) provide support but do not fully offset the current loss-making, cash-consuming profile; valuation is also constrained by negative earnings and no dividend.
Positive Factors
Regulatory Milestone
Orphan Drug designation provides up to seven years of US exclusivity, tax credits, fee waivers and closer FDA engagement. This materially improves development economics, raises partner interest odds, and enhances the commercial downside protection for GRI-0621 over the medium term.
Negative Factors
High Cash Burn
Sustained negative operating and free cash flow of roughly -$13.9M TTM means the company must rely on external funding to advance pivotal programs. Over months this raises dilution risk and can force hurried financings that compress strategic optionality if clinical timelines slip.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory Milestone
Orphan Drug designation provides up to seven years of US exclusivity, tax credits, fee waivers and closer FDA engagement. This materially improves development economics, raises partner interest odds, and enhances the commercial downside protection for GRI-0621 over the medium term.
Read all positive factors
GRI Bio (GRI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.33M
Dividend YieldN/A
Average Volume (3M)83.37K
Price to Earnings (P/E)―
Beta (1Y)2.46
Revenue GrowthN/A
EPS Growth97.37%
CountryUS
Employees3
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-241.87
Shares Outstanding1,770,838
10 Day Avg. Volume187,666
30 Day Avg. Volume83,367
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.11
Price to Sales (P/S)0.00
P/FCF Ratio-0.07
Enterprise Value/Market Cap-3.24
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.39K
Enterprise Value/Ebitda0.77
Forecast
1Y Price Target
$21.00Price Target Upside7400.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-5.26
Revenue Forecast (FY)N/A
GRI Bio Business Overview & Revenue Model
Company Description
GRI Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutic agents within the United States. Its primary focus lies in addressing inflammatory, fibrotic, and autoimmune ...
How the Company Makes Money
null...
GRI Bio Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 22.54M | 0.00 | 0.00 | 0.00 |
| Gross Profit | -2.00K | -4.00K | -4.00K | -57.00K | -50.00K | -73.00K |
| EBITDA | -13.97M | -11.97M | -8.20M | -10.90M | -2.51M | -9.21M |
| Net Income | -13.95M | -11.96M | -8.21M | -13.04M | -3.22M | -9.30M |
Balance Sheet | ||||||
| Total Assets | 11.34M | 8.67M | 5.74M | 2.96M | 383.00K | 218.00K |
| Cash, Cash Equivalents and Short-Term Investments | 11.05M | 8.23M | 5.03M | 1.81M | 9.00K | 90.00K |
| Total Debt | 58.00K | 71.00K | 119.00K | 14.00K | 673.00K | 3.61M |
| Total Liabilities | 794.00K | 2.66M | 1.71M | 2.70M | 2.01M | 4.94M |
| Stockholders Equity | 10.54M | 6.01M | 4.03M | 259.00K | -1.63M | -4.72M |
Cash Flow | ||||||
| Free Cash Flow | -14.27M | -10.19M | -8.61M | -9.00M | -1.09M | -847.00K |
| Operating Cash Flow | -13.87M | -10.19M | -8.61M | -8.99M | -1.08M | -847.00K |
| Investing Cash Flow | -3.00K | -3.00K | 0.00 | -8.00K | -3.00K | 0.00 |
| Financing Cash Flow | 19.89M | 13.39M | 11.83M | 10.80M | 1.01M | 600.00K |
GRI Bio Technical Analysis
Negative
0.28
Price Trends
2.25
Negative
2.42
Negative
20.68
Negative
Market Momentum
-0.02
Negative
38.14
Neutral
51.54
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GRI, the sentiment is Negative. The current price of 0.28 is below the 20-day moving average (MA) of 2.13, below the 50-day MA of 2.25, and below the 200-day MA of 20.68, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 38.14 is Neutral, neither overbought nor oversold. The STOCH value of 51.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GRI.
GRI Bio Risk Analysis
GRI Bio disclosed 54 risk factors in its most recent earnings report. GRI Bio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
GRI Bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $3.33M | -0.21 | -199.52% | ― | ― | 97.37% | |
| ― | $2.48M | -0.24 | -168.95% | ― | ― | 84.00% | |
51 Neutral | $4.94M | -0.61 | -82.17% | ― | -34.06% | 79.61% | |
| ― | $3.48M | -0.06 | -263.57% | ― | -61.81% | 99.68% |
* Healthcare Sector Average
GRI
GRI Bio
1.88
-34.80
-94.87%
OGEN
Oragenics
0.55
-3.01
-84.58%
INM
InMed Pharmaceuticals
1.49
-0.96
-39.18%
KTTA
Pasithea Therapeutics Corp
0.50
-0.22
-30.56%
ONCO
Onconetix
0.94
-200.56
-99.53%
GRI Bio Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
GRI Bio Secures FDA Orphan Drug Status for IPF
Positive
Jun 18, 2026
On June 18, 2026, GRI Bio, Inc. announced that the U.S. Food and Drug Administration granted Orphan Drug Designation to its lead candidate GRI-0621 (tazarotene) for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disea...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and FinancingProduct-Related Announcements
GRI Bio Highlights Promising Phase 2a IPF Data, Outlook
Positive
May 14, 2026
On May 14, 2026, GRI Bio reported first-quarter 2026 results and new Phase 2a data showing its IPF candidate GRI-0621 improved key clinical symptoms and safety measures when added to standard-of-care antifibrotics. In 35 idiopathic pulmonary fibro...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.